Cargando...
Delay of treatment change following objective progression on first-line erlotinib in EGFR-mutant lung cancer
BACKGROUND: Erlotinib is a highly active EGFR kinase inhibitor approved for first-line use in lung cancers harboring EGFR mutations. Anecdotal experience suggests this drug may provide continued disease control following objective progression of disease (PD), however this has not been systematically...
Guardado en:
| Publicado en: | Cancer |
|---|---|
| Autores principales: | , , , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
2015
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4525718/ https://ncbi.nlm.nih.gov/pubmed/25876525 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.29397 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|